Mosunetuzumab is a humanized anti-CD20/CD3 bispecific antibody used to treat relapsed or refractory follicular lymphoma. It can recognize and bind two different targets simultaneously, CD20 on cancer B-cells and CD3 on T-cells, allowing it to redirect T-cell cytotoxic activity to cancer cells.
- Mechanism
- Curator reviewed · 5 references
Mosunetuzumab is a full-length, humanized anti-CD20/CD3 bispecific antibody that targets CD20-expressing B-cells. Unlike B-cell-targeting monoclonal antibodies, such as rituximab, mosunetuzumab can recognize and bind two different targets, CD20 on cancer B-cells and CD3 on T-cells in a 1:1 ratio. Mosunetuzumab is a conditional agonist; the targeted killing of CD20-expressing B-cells is observed only when this drug is simultaneously bound to CD20 on B-cells and CD3 on T-cells. Mosunetuzumab recruits T-cells and leads to their activation by promoting the formation of an immunologic synapse between a target B-cell and a cytotoxic T-cell. The activation of T-cells leads to the directed release of perforin and granzymes through the immunologic synapsis, which ultimately induces B-cell lysis and cell death.
- Primary indication
- Mosunetuzumab as monotherapy is indicated for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) who have received at least two prior systemic therapies.Curator reviewed · 3 structured indications
- Formula / weight
- C6515H10031N1725O2025S43 · 146300.0 Da (approximate)
- First approval
- Canada, 2026 · United States, 2022 · European Union, 2022
- Also known as
- Mosunetuzumab-axgb
- Code names
- BTCT-4465A · RG-7828 · RO-7030816
- Brand names
Resolves to
What you can answer from here — as of January 06, 2026
Which drugs share a target with Mosunetuzumab, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account